Anavex Life Sciences (AVXL) Non Operating Income (2016 - 2025)
Anavex Life Sciences (AVXL) posted Non Operating Income of $1.1 million for Q4 2025, up 10.03% sequentially from $1.0 million in Q3 2025, and down 24.44% YoY from $1.5 million in Q4 2024.
Anavex Life Sciences (AVXL) Non Operating Income (2016 - 2025) Analysis & Trends
Anavex Life Sciences has reported Non Operating Income for 10 years, with the latest figure at $1.1 million in Q4 2025.
- Quarterly Non Operating Income fell 24.44% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.7 million (down 45.7% YoY) and the FY2025 annual result came in at $5.0 million, down 49.05% from the prior year.
- Non Operating Income improved to $1.1 million in Q4 2025 per AVXL's latest filing, from $1.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at $2.8 million in Q4 2023 and troughed at $179800.0 in Q2 2022.
- A 5-year average of $1.5 million and a median of $1.2 million in 2021 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income slumped 85.7% in 2022, then soared 1174.75% in 2023.
- Over 5 years, Non Operating Income stood at $871003.0 in 2021, then jumped by 174.63% to $2.4 million in 2022, then gained by 15.22% to $2.8 million in 2023, then tumbled by 46.26% to $1.5 million in 2024, then slipped by 24.44% to $1.1 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered $1.1 million, $1.0 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 2.08 Mn |
| Dec 31, 2023 | 2.76 Mn |
| Sep 30, 2023 | 2.44 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 2.39 Mn |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 179,800.00 |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 871,003.00 |
| Sep 30, 2021 | 676,743.00 |
| Jun 30, 2021 | 1.26 Mn |
| Mar 31, 2021 | 826,352.00 |